• Mingyan Cong, Janet Chaisson, Dawn Cantrell, Brice L Mohundro, Mollie Carby, Milam Ford, Miao Liu, Lisa S Kemp, Jason Ouyang, Yuan Zhang, Heath C Williams, Benjamin V Vicidomina, and Somesh C Nigam.
• Blue Cross and Blue Shield of Louisiana, 5525 Reitz Ave, Baton Rouge, LA 70809. Email: mingyancong@hotmail.com.
• Am J Manag Care. 2021 Jun 1; 27 (6): 249-254.

ObjectivesTo determine whether elimination of co-pays for prescription drugs affects medication adherence and total health care spending.Study DesignRetrospective comparative study.MethodsWe conducted a difference-in-differences comparison in the year before and after expansion of a Zero Dollar Co-pay (ZDC) prescription drug benefit in commercially insured Louisiana residents. Blue Cross and Blue Shield of Louisiana members with continuous disease management program enrollment were analyzed, of whom 6463 were enrolled in the ZDC program and 1821 were controls who were ineligible because their employers did not opt in.ResultsAfter ZDC expansion, medication adherence fell in the control group and rose in the ZDC group, with a relative increase of 2.1 percentage points (P = .002). Medical spending fell by $71 per member per month (PMPM) (P = .027) in the ZDC group relative to controls. Overall, there was no significant increase in the cost of drugs between treatment and controls. However, when drugs were further categorized, there was a significant increase of $8 PMPM for generic drugs and no significant difference for brand name drugs. Comparisons of medication adherence rates by household income showed the largest relative increase post ZDC expansion among low-income members.ConclusionsElimination of co-pays for drugs indicated to treat chronic illnesses was associated with increases in medication adherence and reductions in overall spending of $63. Benefit designs that eliminate co-pays for patients with chronic illnesses may improve adherence and reduce the total cost of care.

7 keywords...

hide…